TY - JOUR
T1 - Barrett's esophagus
T2 - Proton pump inhibitors and chemoprevention II
AU - Richter, Joel E.
AU - Penagini, Roberto
AU - Pohl, Daniel
AU - Dvorak, Katerina
AU - Goldman, Aaron
AU - Savarino, Edoardo
AU - Zentilin, Patrizia
AU - Savarino, Vincenzo
AU - Watson, Joshua T.
AU - Wong, Roy K H
AU - Pace, Fabio
AU - Casini, Valentina
AU - Peura, David A.
AU - Herzig, Shoshana Joy
AU - Kamiya, Takeshi
AU - Pelosini, Iva
AU - Scarpignato, Carmelo
AU - Armstrong, David
AU - Devault, Kenneth R.
AU - Bechi, Paolo
AU - Taddei, Antonio
AU - Freschi, Giancarlo
AU - Ringressi, Maria Novella
AU - Degli'Innocenti, Duccio Rossi
AU - Castiglione, Francesca
AU - Masini, Emmanuella
AU - Hunt, Richard H.
PY - 2011/9
Y1 - 2011/9
N2 - The following on proton pump inhibitors (PPIs) and chemoprevention in relation to Barrett's esophagus includes commentaries on 48-h pH monitoring, pH-impedence, bile acid testing, dyspepsia, long/short segment Barrett's esophagus, nonerosive reflux disease (NERD), functional heartburn, dual-release delivery PPIs, immediate-release PPIs, long-term PPI use, prokinetic agents, obesity, baclofen, nocturnal acid breakthrough, nonsteroidal anti-inflammatory drugs (NSAIDs), and new PPIs.
AB - The following on proton pump inhibitors (PPIs) and chemoprevention in relation to Barrett's esophagus includes commentaries on 48-h pH monitoring, pH-impedence, bile acid testing, dyspepsia, long/short segment Barrett's esophagus, nonerosive reflux disease (NERD), functional heartburn, dual-release delivery PPIs, immediate-release PPIs, long-term PPI use, prokinetic agents, obesity, baclofen, nocturnal acid breakthrough, nonsteroidal anti-inflammatory drugs (NSAIDs), and new PPIs.
KW - 48-h acid reflux monitoring
KW - ACG guidelines
KW - Acid suppression
KW - API-023
KW - AspECT trial
KW - Baclofen
KW - Barrett's esophagus
KW - Bile acids
KW - Bilitec probe
KW - Clostridium difficile
KW - CMA omeprazole
KW - COX-2 inhibitors
KW - Dexlansoprazole
KW - Erosive esophigitis
KW - Functional dyspepsia
KW - Functional heartburn
KW - Fundic glands polyp
KW - GABA
KW - GERD
KW - Ilaprazole
KW - NERD
KW - Nocturnal acid breakthrough
KW - PH testing
KW - Pharmacokinetic changes
KW - PPI therapy
KW - Rabeprazole
KW - STU-Na
KW - Symptom Association Probability
KW - Tenatoprazole
KW - TLESR
UR - http://www.scopus.com/inward/record.url?scp=80053198166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053198166&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2011.06048.x
DO - 10.1111/j.1749-6632.2011.06048.x
M3 - Article
C2 - 21950810
AN - SCOPUS:80053198166
VL - 1232
SP - 114
EP - 139
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
SN - 0077-8923
IS - 1
ER -